OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Cancer is 91. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives	746
Circular RNA: metabolism, functions and interactions with proteins	550
The potential role of RNA N6-methyladenosine in Cancer progression	512
mRNA vaccine for cancer immunotherapy	452
Targeting STAT3 in Cancer Immunotherapy	437
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions	422
The cancer metabolic reprogramming and immune response	402
Ferroptosis in cancer therapy: a novel approach to reversing drug resistance	381
Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects	372
Natural killer cells in cancer biology and therapy	344
Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma	292
Glioma targeted therapy: insight into future of molecular approaches	285
Exosomes as a new frontier of cancer liquid biopsy	281
RETRACTED ARTICLE: LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis	279
Targeting TGF-β signal transduction for fibrosis and cancer therapy	257
Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy	252
Exosomal circPACRGL promotes progression of colorectal cancer via the miR-142-3p/miR-506-3p- TGF-β1 axis	252
Exosome-based immunotherapy: a promising approach for cancer treatment	250
The role of m6A, m5C and Ψ RNA modifications in cancer: Novel therapeutic opportunities	248
G-quadruplexes: a promising target for cancer therapy	246
Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments	243
Exosomal circSHKBP1 promotes gastric cancer progression via regulating the miR-582-3p/HUR/VEGF axis and suppressing HSP90 degradation	240
Wnt signaling in colorectal cancer: pathogenic role and therapeutic target	233
PARP inhibitor resistance: the underlying mechanisms and clinical implications	231
LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes	227

Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities	226
RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner	223
The role of m6A RNA methylation in cancer metabolism	214
CircRNA inhibits DNA damage repair by interacting with host gene	197
The role of ubiquitination and deubiquitination in cancer metabolism	194
Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc	191
mRNA vaccine: a potential therapeutic strategy	186
METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer	183
Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance	180
Circular RNAs in body fluids as cancer biomarkers: the new frontier of liquid biopsies	179
Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments	179
Circular RNA circSATB2 promotes progression of non-small cell lung cancer cells	173
The role of N6-methyladenosine (m6A) modification in the regulation of circRNAs	171
Mechanism of RNA modification N6-methyladenosine in human cancer	171
mRNA therapeutics in cancer immunotherapy	169
Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine	167
N6-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling	164
Long noncoding RNAs: functions and mechanisms in colon cancer	164
Interaction between N6-methyladenosine (m6A) modification and noncoding RNAs in cancer	162
ALKBH5 suppresses malignancy of hepatocellular carcinoma via m6A-guided epigenetic inhibition of LYPD1	159
YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer	153
N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer	152
m6A modification: recent advances, anticancer targeted drug discovery and beyond	149
Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer	147
Novel insights into the interplay between m6A modification and noncoding RNAs in cancer	144
Lung cancer immunotherapy: progress, pitfalls, and promises	144
Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook	141
Cuproptosis: mechanisms and links with cancers	136
Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis	135
Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer	135
Upregulation of METTL14 mediates the elevation of PERP mRNA N6 adenosine methylation promoting the growth and metastasis of pancreatic cancer	134
METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer	134
Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring	131
circCUL2 regulates gastric cancer malignant transformation and cisplatin resistance by modulating autophagy activation via miR-142-3p/ROCK2	131
Comprehensive landscape of extracellular vesicle-derived RNAs in cancer initiation, progression, metastasis and cancer immunology	130
cGAS-STING pathway in cancer biotherapy	127
Cancer associated-fibroblast-derived exosomes in cancer progression	127
Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer	126
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer	125
EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3	122
The circular RNA circ-ERBIN promotes growth and metastasis of colorectal cancer by miR-125a-5p and miR-138-5p/4EBP-1 mediated cap-independent HIF-1α translation	122
A novel protein encoded by circMAPK1 inhibits progression of gastric cancer by suppressing activation of MAPK signaling	120
Circular RNA circCCDC9 acts as a miR-6792-3p sponge to suppress the progression of gastric cancer through regulating CAV1 expression	120
Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy	118
Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis	113
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy	106
CircECE1 activates energy metabolism in osteosarcoma by stabilizing c-Myc	106
circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer	106
Circular RNA hsa_circ_0004872 inhibits gastric cancer progression via the miR-224/Smad4/ADAR1 successive regulatory circuit	106
Expression profiles, biological functions and clinical significance of circRNAs in bladder cancer	105

Progress on pivotal role and application of exosome in lung cancer carcinogenesis, diagnosis, therapy and prognosis	103
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing	101
Cancer cell-derived exosomal circUSP7 induces CD8+ T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC	100
RETRACTED ARTICLE: CircTLK1 promotes the proliferation and metastasis of renal cell carcinoma by sponging miR-136-5p	100
LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM	98
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy	98
DDX3X: structure, physiologic functions and cancer	97
Circ3823 contributes to growth, metastasis and angiogenesis of colorectal cancer: involvement of miR-30c-5p/TCF7 axis	97
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer	96
Proteolysis-targeting chimeras (PROTACs) in cancer therapy	95
Circular RNA circ_0020710 drives tumor progression and immune evasion by regulating the miR-370-3p/CXCL12 axis in melanoma	95
Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab	94
Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development	93
Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments	93
The FUS/circEZH2/KLF5/ feedback loop contributes to CXCR4-induced liver metastasis of breast cancer by enhancing epithelial-mesenchymal transition	91
LINC00173.v1 promotes angiogenesis and progression of lung squamous cell carcinoma by sponging miR-511-5p to regulate VEGFA expression	91